Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024Journal of Advanced ResearchOpen Access

Efficient chemo-immunotherapy leveraging minimalist electrostatic complex nanoparticle as “in situ” vaccine integrated tumor ICD and immunoagonist

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYunfei HanMJMingxia JiangYSYanju Sun

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Han et al. (2024) studied this question.

synapsesocial.com/papers/68e76333b6db6435876d8f85https://doi.org/10.1016/j.jare.2024.03.010
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An acid-responsive nanoagonist delivering chemotherapy-derived tumor antigens to assist cancer immunotherapy2026
  2. 2Synergistic Cancer Immunotherapy by Inducing Immunogenic Cell Death and Blocking the CD39-Adenosine Pathway Using a Nanoplatform2026
  3. 3Cancer nanovaccine plus doxorubicin and immune checkpoint blockade overcomes chemoresistance and delays postsurgical recurrence2026
  4. 4Combination Nanodrug Delivery Systems Facilitate the Syncretism of Chemotherapy with Immunotherapy to Promote Cancer Treatment2024 · 14 citations
  5. 5Targeted Liposomal Co-delivery of an Immunogenic Cell Death Inducer and a Toll-Like Receptor 4 Agonist for Enhanced Cancer Chemo-immunotherapy2024 · 18 citations